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Glycemic Control and Hypoglycemia
Is the loser the winner?
G
lycemic control remains a delicate
balancing act. The diabetic patient
is tasked with maintaining euglyce-
mic blood glucose levels, a goal requiring
education, decision strategies, volitional
control, and the wisdom to avoid hyper-
andhypoglycemia,withthelatterdeﬁned
as plasma glucose less than 60 mg/dl.
Glucose levels must be controlled contin-
uously and without holidays. Failure to
maintain euglycemia results from biolog-
ical factors and psychosocial factors
including overmedication and/or inap-
propriate choices regarding food, drink,
and, in certain cases, exercise.
Diabetic patients, especially those
treated with insulin, are at risk for devel-
oping hypoglycemia. Treatment, even
withoralagentssuchassulfonylureas,in-
creases this risk. Asymptomatic episodes
of hypoglycemia may constitute up to
10% of a 24-h period in diabetic patients
(1,2).Individualswithtype1diabetesav-
erage 43 symptomatic episodes annually;
insulin-treatedindividualswithtype2di-
abetes average 16 episodes (3). As for
severe hypoglycemic episodes, patients
with type 1 diabetes experience up to
twoepisodesannually,whereaspatients
with type 2 diabetes experience about
one episode over 5 years. The risk in-
creases with a history of hypoglycemia
and an increased number of years of in-
sulin treatment (3,4).
Hypoglycemia deprives the brain of
the constant supply of glucose needed for
energy. Such low levels of blood glucose
are sensed by the ventromedial hypothal-
amus (5). In turn, a counterregulatory
hormonal cascade is activated to rapidly
restore euglycemia that begins with inhi-
bition of insulin secretion. Thereafter, the
release of glucagon and epinephrine ele-
vates endogenous glucose production
through increased hepatic glycogenolysis
and gluconeogenesis, as well as renal glu-
coneogenesis. Growth hormone and cor-
tisol are slow-acting adjustments to
prolonged hypoglycemia (6). Hypoglyce-
mia may promote oxidative stress and
neuronal cell death, primarily as a conse-
quence of neuronal NADPH oxidase acti-
vation and extracellular zinc release
duringglucosereperfusion.Thus,height-
ened glucose concentrations during
reperfusion can lead to cell death (7).
Counterregulatory responses also stimu-
late the sympathetic autonomic nervous
system, resulting in symptoms of sweat-
ing, trembling, anxiety, hunger, and ner-
vousness. Deprivation of glucose triggers
neuroglycopenic symptoms, including
confusion and irritability (8).
Severe hypoglycemic episodes often
occur during sleep, when the intensity
and recognizability of counterregulatory
responses tend to be diminished, thereby
depriving individuals of the adequate
stimulus to counteract hypoglycemia (9).
These episodes, termed nocturnal hypo-
glycemia (NH), may result in part from
insufﬁcient food intake and/or inappro-
priate insulin dosage the previous even-
ing. Asymptomatic NH is a relatively
common phenomenon affecting up to
50% of adults and 78% of children and
lasting as long as several hours (10).
Moreover, NH is suspected to contribute
to the “dead-in-bed syndrome” that leads
to the mortality of 6% of type 1 diabetic
individualsbelowtheageof40years(11).
In addition to NH, individuals may
also fail to recognize hypoglycemic epi-
sodes during the day. Such desensitiza-
tion is due to decreased neuroendocrine
responses to hypoglycemia that dampen
symptomatic responses (12). Men are
more prone to desensitization, whereas
women inherently exhibit decreased
counterregulatory responses to hypogly-
cemia(13).Thus,inbothsexes,thewarn-
ing signs and symptoms of hypoglycemia
are typically not exhibited until blood
glucose drops to dangerously low levels.
Even two episodes of moderate hypogly-
cemia are sufﬁcient to decrease counter-
regulatory hormonal responses to
hypoglycemia (14). Hence, as has been
said, hypoglycemia begets hypoglycemia
(15).
Hypoglycemia-associated autonomic
failure may also result from intense phys-
icalactivity.Exercise-inducedhypoglyce-
mia occurs up to 17 h after cessation of
physical activity and can result from in-
creased insulin sensitivity and glucose
utilization. Furthermore, counterregula-
tory responses may be reduced by 50%
during hypoglycemia following moder-
ately intense exercise (16).
From a practical perspective, a 10-s
“sprint” of maximal effort immediately
before or after moderately intense physi-
cal activity may reduce the rapid fall in
glucose level associated with exercise.
The sprint stabilizes glycemia in the
period of early recovery from exercise,
possibly by facilitating the release of
counterregulatory response hormones
(17,18).
Fear of hypoglycemia
While the symptoms of hypoglycemia
alert individuals to an impending epi-
sode, these warning signs can diminish
quality of life and reduce glycemic con-
trol. These symptoms may elicit anxiety
and fear of future hypoglycemia. In addi-
tion, the observation of a hypoglycemic
eventmayelicitevengreaterfearinfamily
members(19)andinnondiabeticspouses
than in the patient (20). Hypoglycemic
episodes may provoke marital conﬂict re-
garding diabetes management (21), and
suchexperiencesofstressandconﬂictcan
further raise glucose levels (22). Finally,
in an effort to prevent future hypoglyce-
mic episodes, an individual may resort to
behaviors (e.g., reducing or eliminating
insulin dose and/or consuming high–
glycemic index food) that increase glu-
cose levels.
Thesubjectiveexperienceofhypogly-
cemia is inﬂuenced by ambient glucose
levels. Higher resting levels of glucose
may falsely increase an individual’s sensi-
tivity to the symptoms of hypoglycemia.
Thus,preventativeactionmaybeinitiated
to increase blood glucose levels that are
already above normal, thereby further
worseningglycemiccontrol.Ontheother
hand, tight glycemic control can lead to
hypoglycemia desensitization and re-
duced recognition of symptoms, thus
risking a more severe drop in blood glu-
cose (23). Hence, good glycemic control
may constitute a Pyrrhic victory.
The inconsistent outcomes of tight
glycemic control have spawned extensive
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cedents and consequences. One such
consequence, recurrent hypoglycemia,
has been linked to neuronal and retinal
cell death, reductions in gray matter, per-
sistent cognitive dysfunction, and even
developmental growth deﬁciencies (24–
27). The Diabetes Control and Complica-
tions Trial (DCCT) was initiated in 1983
to examine the beneﬁcial effects of tight
glycemiccontrolonreducingdiabetesco-
morbidities. The study’s principal ﬁnding
was that intensive therapy selectively re-
duced diabetes-related complications
compared with conventional therapy
(28). However, improved glycemic con-
trol came with a cost: severe hypoglyce-
mic episodes. Severe hypoglycemic
episodes—those requiring assistance of
another individual to avoid or respond to
seizure or coma—occurred three times
moreoftenintheintensivetherapygroup.
Hypoglycemia was a factor in the deaths
of at least three individuals participating
in the DCCT and was found to contribute
to 2–4% of deaths in diabetic patients
(28,29).
Oneimportantconclusionfromthese
studies was that hypoglycemia was not an
equal opportunity outcome. Moderating
these outcomes are age, sex, severity of
hypoglycemia, number of such events,
certain diabetes and hypertension medi-
cations, and disease duration (13,14,30–
32). When is tight control a form of
glycemic hormesis?
The stability of blood glucose levels is
complicated by several factors, including
circadian rhythms, stress, insulin sensi-
tivity, and time of day (33). In addition,
certaingeneticfactors(e.g.,levelsofACE)
can predispose diabetic patients to severe
hypoglycemia (34). Furthermore, a re-
cent study has shown that current smok-
ers have an increased risk for severe
hypoglycemia,whichtheinvestigatorsat-
tributed to the decreased insulin clear-
ance associated with smoking (35).
Short-term consequences
The acute sequela of mild hypoglycemic
episodes includes decrements in motor
skills, visual acuity, auditory processing,
mood,andavarietyofcognitiveprocesses
(36–40). It is unclear whether age mod-
erates the level of decline exhibited with
mild hypoglycemic episodes. However,
hypoglycemic criteria can vary by age:
healthy children may experience hypo-
glycemia-induced neurological impair-
ment at 75 mg/dl and healthy young
adults at 54 mg/dl (41).
Therateatwhichglucosedecreasesin
acute hypoglycemia also affects cogni-
tion. In a hyperinsulinemic clamp study
with type 1 diabetic adults in the post-
prandial state, a fast decline in blood glu-
cose following rapid-acting insulin
injection reduced the counterregulatory
response and increased cognitive dys-
function (42).
Long-term consequences
The longitudinal study by Musen et al.
(43)featuredinthisissueofDiabetesCare
concluded that despite many severe hy-
poglycemic events, there was no measur-
able decline in cognition over 18 years.
While their summary is generally accu-
rate, more detailed examinations may be
inconsistent with their conclusion. First,
potentialparticipantswereexcludedfrom
the DCCT if they had a history of severe
hypoglycemic reactions, thus limiting the
generalizability of the study. Second, 74
individuals chose to discontinue their
participation in the Musen et al. study
(43), and only 18 of these individuals
were accounted for, leaving 56 potential
participants unaccounted for. Perhaps
these 56 people suffered from more se-
vere hypoglycemic events and/or related
cognitive deterioration and terminated
their participation. Thus, this discontinu-
ance may be an instance of nonrandom
dropout. To further address this possible
source of bias, the presentation of com-
pletebaselinedataforthedropoutswould
have been useful. Third, it was unclear
how old the individuals were when they
experienced each severe hypoglycemic
episode.Fourth,thestatisticalsupportfor
evaluating the possible synergistic effects
of hyperglycemia and hypoglycemia on
cognitive function was not reported. The
association between elevated A1C and
poorer cognitive performance gives more
urgencytothepossibleassociationofcog-
nition with hypoglycemic and hypergly-
cemic episodes (28,43,44). Finally, the
adolescent sample was of above-average
intelligence at the start of the DCCT (IQ
110)andincludedrelativelyfewminor-
ities. In summary, despite this study’s
wealth of data, the relationship between
hypoglycemia and cognition remains
somewhat difﬁcult to decipher.
Contradictory ﬁndings
Studies on the long-term effects of severe
hypoglycemia on cognition have pro-
duced mixed results. The age at which
severe hypoglycemic episodes occur
moderates the effects on cognition
(27,30,45). Brain developmental stages
before adolescence provide a unique re-
source for evaluating acute and chronic
effects of hypoglycemia on cognition. For
example, structural abnormalities existed
in the occipital lobes of 82% of newborns
who experienced severe non–diabetes-
related hypoglycemia and led to visual
impairmentinhalfofthesample(46).Re-
currentmoderatehypoglycemiaininfants
resulted in reduced head circumference
and lower psychometric scores at age 5
years (27). Several studies conducted on
children (ages 5–18 years) have found
that the number of hypoglycemia-
induced seizures was a predictor for de-
creased motor skills, memory, attention,
andverbalIQ(47–49).Asimilarstudyon
the impact of severe hypoglycemic epi-
sodes on children found no impairments
infull-scaleIQ,planning,orattentionbut
did not examine memory or verbal IQ
(50).
It has been suggested that the medial
temporal lobe, involved in memory, is
particularly sensitive to hypoglycemic in-
sult. Declarative memory (factual mem-
ory) and spatial memory have been
shown to inversely correlate with the
number of severe hypoglycemic episodes
in children (51,52). Even mild hypogly-
cemia during sleep impaired consolida-
tion of declarative memory (53). Thus, in
children,hypoglycemiamayhavebothan
immediate and long-term effect on de-
clarative memory.
Relatively few studies have examined
cognitive effects of hypoglycemia in adult
diabetic patients. Adults diagnosed with
type 1 diabetes after the age of 19 years
exhibited lower full-scale IQ scores as the
number of severe hypoglycemic episodes
increased (45). Moreover, in hyperinsu-
linemic middle-aged patients free of dia-
betes, cognition declined as a result of
exposure to hypoglycemic events (54).
Mechanisms secondary to
hypoglycemia: adults and children
Hypoglycemia appears to be more closely
associated with cognitive problems in
children than in adults, although the ma-
jority of such studies occur in children.
Reduced counterregulatory responses in
adults may be responsible for this rela-
tionship. We propose that a delayed and
weaker counterregulatory effect may be
protective, i.e., that the gradual reperfu-
sion of cerebral tissue after a hypoglyce-
mic event may reduce cognitive damage
resulting from oxidative stress (7,14).
Thus, individuals with an impaired coun-
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derly) may be spared the immediate and
harmfuleffectsofrapidreperfusiononce-
rebral tissue.
In addition, acute hypoglycemia may
temporarily affect the cardiovascular sys-
tem; however, in those with endothelial
dysfunction, these changes can trigger ma-
jor cardiovascular events, including myo-
cardial and cerebral ischemia (55).
Hypoglycemiaalsoinducesdistinctmodiﬁ-
cations in cardiac repolarization (decreases
in the height and width of the T-wave
and/or lengthened corrected QT interval),
which may heighten susceptibility to car-
diac arrhythmias (56,57).
Anxiety and depression
Hypoglycemia adversely alters mood. Re-
current hypoglycemia elevates anxiety,
depression, and anergia (36,39). Such
changes in emotion are usually associated
with a decreased self-reported energy
level and self-efﬁcacy that can degrade
cognitive performance. Of particular im-
portance is that in depression, selective
serotonin reuptake inhibitors are associ-
ated with a progressively increased risk of
severe hypoglycemia (58). Other types of
antidepressants may be more appropriate
for diabetic individuals with high risk of
severe hypoglycemia.
Interacting effects of multiple
treatment methods
Additionally, several medications have
been shown to increase the risk of hypo-
glycemia. A selective review of the litera-
ture indicates that levothyroxine was
associated with an increased risk of hypo-
glycemia in Japanese patients with liver
impairment (59). ACE inhibitors may in-
crease the risk of hypoglycemia in dia-
betic individuals compared with other
antihypertensive drugs, possibly by in-
creasing insulin sensitivity (31). Short-
acting insulin analogues (lispro, aspart,
and glulisine) have better postprandial
glycemic control without intensifying
theriskofhypoglycemiacomparedwith
human insulin (32). Finally, the insulin
pump appears to improve glycemic
control, reduce episodes of hypoglyce-
mia, and increase quality of life more
effectivelythanmultiple-daily-injection
therapy (60).
Oral antihyperglycemic agents, espe-
cially sulfonylureas, increase the risk of
hypoglycemia. However, third-genera-
tionsulfonylureashavedecreasedtherisk
of hypoglycemia to 0.8 episodes/1,000
patient-years down from the 5.6 epi-
sodes/1,000 patient-years rate associated
with second-generation sulfonylureas.
Combination therapy with sulfonylureas
and insulin remains risky (61).
Antidote to hypoglycemia
Recent animal studies have shown that
treatment for brain damage incurred dur-
ing severe hypoglycemic episodes is pos-
sible. The same excitotoxic mechanism
thatdestroysneuronsfollowingastrokeis
thought to destroy neurons during hypo-
glycemia. N-methyl-D-aspartate
(NMDA)- and -amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid
(AMPA)-receptor antagonists, currently
used to treat stroke patients, are being as-
sessedforefﬁcacyintreatingseverehypo-
glycemia. These studies have shown that
these drugs reduced hypoglycemia-
induced striatal and neocortical damage,
as well as hippocampal seizures (62,63).
Conclusion
Hypoglycemia is a vital issue for patients
andtheirfamilies.Diabeteseducationcan
provide patients with options that reduce
fearanddiscouragechoicesthatprovidea
rationale for poor glycemic control. Fi-
nally, until stronger evidence is found, it
appearsthatthebeneﬁtsofgoodglycemic
control still outweigh the risks. Maintain-
ing balance is key.
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